Stevanato Group SpA (STVN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Stevanato Group SpA stock $7.91, price $13.57, that is 41.7% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $13.21 – $35.16 · fair‑value band $4.02 – $13.01 · the $13.57 price screens above the $7.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Stevanato Group SpA in your weekly email
Every Wednesday you see whether Stevanato Group SpA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Show moreShow less
It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services.
It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers.
The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Stock analysis
Stevanato Group SpA (STVN) currently trades at $13.57, while our model-based Fair Value estimate is $7.91, 42% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $11.69 per share, and 2 of the 26 models we run sit above the $13.57 price.
Bear case: the Dividend Discount group reads lowest at $0.9700, and 24 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: $4.02 (bear) to $13.01 (bull), the price of $13.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Stevanato Group SpA reported revenue of €1.1B in FY2025 versus €844M in FY2021, a compound +7.8%/yr. Reported net income was €134M in FY2025, compounding 0.0%/yr from FY2021.
Key figures
Market cap $3.7B Mid · P/E ratio 22.8 · P/S ratio 2.71 · EPS (TTM) $0.5900 · Dividend yield 0.4% · Net margin 11.0% · Return on equity 9.1% · Return on assets (EBIT) 9.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −42%, STVN screens cheaper than that median.
Fair Value models
Bear$4.02Fair Value $7.91Bull$13.01
Price $13.57 · Downside -41.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.5043 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 8 officers or directors sold shares worth $561,800 and none bought.
SaleMauro StocchiOfficer13,649 shares at $21.50$293,454Sep 28, 2026
SaleElisabetta MagistrettiDirector2,045 shares at $20.09$41,084Aug 7, 2026
SaleLago Marco DalChief Financial Officer4,209 shares at $20.09$84,559Aug 7, 2026
SaleLuciano SantelDirector2,023 shares at $20.09$40,642Aug 7, 2026
SaleWilliam J FedericiDirector1,493 shares at $17.09$25,515Jun 15, 2026
SaleKaren FlynnDirector1,493 shares at $17.09$25,515Jun 15, 2026
SaleDonald E Morel JrDirector1,493 shares at $17.09$25,515Jun 15, 2026
SaleMadhavan BalachandranDirector1,493 shares at $17.09$25,515Jun 15, 2026
Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+11.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.6%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 16%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+50.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +47.5% a year for the price and +3.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Leads in pharmaceutical packaging components with a global network of sites yet modest returns on equity limit durable moat assessment.
Main risk: Execution risks when ramping new facilities in Italy and the US could slow margin expansion.
Stevanato Group leads in key pharmaceutical packaging components with a global network of 13 sites. Ramping new capacity in Italy and the US offers scale in high-value solutions but carries clear execution risks that could slow margin expansion. Our models see the shares as overvalued. Will the new facilities deliver leverage faster than peers adapt to shifting supply chains?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 7/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−41.7% · Below median
Profitability
Return on equity (12 months)9.1% · Above median
Return on assets5.3% · Above median
Net margin (12 months)11.0% · Above median
Operating margin (12 months)17.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)7.8% · Below median
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.23× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Stevanato Group SpA Fair Value". https://www.fairvalue-calculator.com/stock/STVN
Frequently asked questions
Is Stevanato Group SpA (STVN) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $7.91 versus a price of $13.57, about 42% lower (overvalued).
What is the fair value of STVN?
Our model-based fair value for Stevanato Group SpA is $7.91 (as of Nov 5, 2026), built from audited fundamentals. The current price: $13.57.
What is the quality score of STVN?
Stevanato Group SpA has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Stevanato Group SpA (STVN)?
Our model-based price target is the fair value of $7.91 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario $4.02, optimistic scenario $13.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Stevanato Group SpA stock forecast for 2026?
Our models put fair value at $7.91, about 42% lower versus a price of $13.57 (overvalued). Cautious scenario $4.02, optimistic scenario $13.01. The calculation is refreshed regularly with new filings.
What is the revenue of Stevanato Group SpA (STVN)?
Stevanato Group SpA reported trailing-twelve-month revenue of about €1.2B (latest available figure, as of Nov 5, 2026).
Does Stevanato Group SpA pay a dividend?
Stevanato Group SpA currently shows a dividend yield of 0.43% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Stevanato Group SpA (STVN)?
Stevanato Group SpA has a dividend yield of 0.4%.
What growth is priced into Stevanato Group SpA (STVN)?
For today's price to be fair in a discounted-cash-flow model, Stevanato Group SpA would have to grow free cash flow by +50.7 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.5 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of STVN use?
Our models discount Stevanato Group SpA at 9.2 %: a base by market capitalisation (mid), damped by beta 0.80, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Stevanato Group SpA that is +50.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Stevanato Group SpA (STVN) delivered so far?
Over the past 5 years revenue at Stevanato Group SpA grew +11.5 % a year. The price currently implies free-cash-flow growth of +50.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Stevanato Group SpA (STVN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Stevanato Group SpA (+50.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Stevanato Group SpA (STVN)?
The free-cash-flow yield on the price is 0.64 %: that much free cash flow Stevanato Group SpA produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Stevanato Group SpA (STVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Stevanato Group SpA it is $7.91 per share (as of Nov 5, 2026), against a price of $13.57. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Stevanato Group SpA stock overvalued or undervalued in 2026?
As of Nov 5, 2026, STVN trades above its calculated fair value: price $13.57, fair value $7.91, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STVN?
No. The price is what the market pays today ($13.57); the fair value is what the company's own numbers justify ($7.91). For Stevanato Group SpA the two are $5.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Stevanato Group SpA worth?
The market values Stevanato Group SpA at about $3.7B (market capitalisation, as of Nov 5, 2026). Per share that is $13.57; our models calculate a fair value of $7.91 per share.
What do the bullish and bearish scenarios say about STVN?
Our models span a range for Stevanato Group SpA: cautious scenario $4.02, base $7.91, optimistic $13.01 per share (as of Nov 5, 2026, price $13.57). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of STVN?
Stevanato Group SpA trades at a price-to-earnings ratio of 22.8 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.91 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 39.1. Other multiples: PEG 1.0, P/B 2.2, P/S 2.7, EV/EBITDA 11.8.
What is the PEG ratio of STVN?
The PEG ratio of Stevanato Group SpA is 1.01 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Stevanato Group SpA (STVN)?
Balance-sheet figures for Stevanato Group SpA (as of Nov 5, 2026): return on equity 9.1%, debt of 0.23 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is STVN from its 52-week high?
Stevanato Group SpA trades at $13.57, about 44% below its 52-week high of $24.32 and 3% above the low of $13.21 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.91 is for.
Which stocks are comparable to Stevanato Group SpA?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Stevanato Group SpA stock attractive at the current price?
The data as of Nov 5, 2026: price $13.57, calculated fair value $7.91 (−42%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of STVN calculated?
We run Stevanato Group SpA through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.91 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Stevanato Group SpA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Stevanato Group SpA (STVN)?
The closing price on Nov 6, 2026 was $13.57. Our model-based fair value is $7.91, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Stevanato Group SpA right now?
The price sits above even our optimistic bull case ($13.01). The favourable scenario is already priced in. The model range is unusually wide ($4.02 to $13.01). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Stevanato Group SpA
How large is the market capitalisation of Stevanato Group SpA (STVN)?
The market capitalisation of Stevanato Group SpA is $3.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Stevanato Group SpA (STVN)?
The price-to-sales ratio of Stevanato Group SpA is 2.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Stevanato Group SpA (STVN)?
Earnings per share at Stevanato Group SpA are $0.5900 (price ÷ EPS = P/E 22.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Stevanato Group SpA (STVN)?
The dividend yield of Stevanato Group SpA is 0.4% (payout 9.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Stevanato Group SpA (STVN)?
The net margin of Stevanato Group SpA is 11.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Stevanato Group SpA (STVN)?
The return on equity (ROE) of Stevanato Group SpA is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Stevanato Group SpA (STVN)?
On an EBIT basis the return on assets of Stevanato Group SpA is 9.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Stevanato Group SpA (STVN)?
The operating margin of Stevanato Group SpA is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Stevanato Group SpA (STVN)?
Revenue at Stevanato Group SpA is growing +7.8% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Stevanato Group SpA (STVN)?
Earnings per share at Stevanato Group SpA are growing −26.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Stevanato Group SpA (STVN) carry?
The net debt of Stevanato Group SpA is €340M (fiscal year 2025, ≈ 15.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Stevanato Group SpA in the live analysis
One click puts Stevanato Group SpA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026